Not actual patients. LYNAVOY is not approved for use in children.
Request a representative
Not actual patients. LYNAVOY is not approved for use in children.
Success!
Thank you for signing up.
Liver Test Elevations were observed more commonly in LYNAVOY-treated patients compared to placebo-treated patients.
Diarrhea was reported as the most common adverse reaction in patients treated with LYNAVOY.
Fat-Soluble Vitamin (FSV) Deficiency: LYNAVOY may adversely affect absorption of FSV (i.e., vitamins A, D, E, and K).
The most common adverse reactions (≥5%) are diarrhea, abdominal pain, nausea, increased ALT, hemorrhage, increased AST, headache, dyspepsia, gastroesophageal reflux disease, abdominal distension, dizziness, and arthralgia.
To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals 1-844-782-4278 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Please see the full Prescribing Information for LYNAVOY.
LYNAVOY (linerixibat) is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients.
Limitations of Use: Avoid use of LYNAVOY in patients with decompensated cirrhosis or those with prior or active hepatic decompensation events (e.g. variceal hemorrhage, ascites, hepatic encephalopathy).